Literature DB >> 29938464

Factors Predictive of Quality of Life among Breast Cancer Patients

Amira Daldoul1, Wieme Khechine, Hanene Bhiri, Nouha Ammar, Rym Bouriga, Mohamed Wassim Krir, Said Soltani, Olfa Zoukar, Mohamed Salah Rhim, Sarra Bouslah, Sabrine Dimassi, Ibtissem Abbess, Zahra Saidani, Sonia Zaied.   

Abstract

Background: Due to progress in medical care, the number of survivors from cancer has increased significantly during recent years and this raises the question of the quality of life (QoL), especially of the many women treated for a breast cancer. This paper focuses on correlations of QoL with anxiety and depression on the one hand and with socio demographic, anatomo-clinical and therapeutic parameters on the other.
Methods: In this cross-sectional study, seventy patients were enrolled and filled in two auto-questionnaires, both in validated Arabic versions: The SF-36 for assessment of QoL and the Hospital Anxiety and Depression Scale (HAD-S) for evaluation of anxiety and depression. The statistical approaches used to determine predictive factors were bivariate correlations to determine relationships between quantitative variables, and T-tests and one-way Anova to analyze links between qualitative and quantitative variables.
Results: The QoL of patients was altered with an SF-36 mean total score of 54.0 ± 22.7, and the alteration affects the different aspects. The mean scores for anxiety and depression in patients were 6.91 ± 4.72 and 6.24 ± 3.88, respectively. The results of this study suggested an association between the QoL and chemotherapy (p= 0.014) and its adverse effects (p=0.01), as well as anxiety (p= 0.0001) and depressive symptoms (p= 0.0001). Socio-demographic factors, the stage of the cancer, and surgery, radiotherapy or hormone therapy did not appear to have significant effects.
Conclusion: The management of breast cancer patients needs a collaborative approach between oncologists, gynecologists, psychologist and psychiatrists. Creative Commons Attribution License

Entities:  

Keywords:  Breast cancer; quality of life; anxiety; depression

Mesh:

Year:  2018        PMID: 29938464      PMCID: PMC6103599          DOI: 10.22034/APJCP.2018.19.6.1671

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Breast cancer is a major public health problem because of its frequency, its cost, its severity and its impact on the physical and psychological health (Jemal et al., 2010). In Tunisia, breast cancer ranks first among womens cancers with a rate of 30%. Diagnosis and treatment’s considerable progress in breast cancer have contributed to a significant increase in the patients’ survival. Nowadays, breast cancer is becoming almost a chronic disease controlled by a long-term treatment. Thanks to these progresses, patients’ quality of life is becoming more and more important and its evaluation is of increasing interest (Zainal et al., 2013). Despite this, few studies have investigated prospectively the quality of life of patients with breast cancer using standardized and validated instruments. This paper will focuses on evaluating the quality of life of women with breast cancer and its correlation with anxiety and depression on the one hand, and with socio demographic, anatomo-clinical and therapeutic parameters on the other hand.

Materials and Methods

This was a cross-sectional study carried out between December 2016 and June 2017. Patients were recruited in the medical oncology department at the Fattouma Bourguiba University Hospital of Monastir in Tunisia. Inclusion criteria were: giving informed consent to participate in the study; histological Evidence of breast tumor malignancy; age between 18 and 70 years; ability to read and understand Arabic language. Exclusion criteria were: severe cognitive impairment (such as Alzheimer’s disease); serious psychiatric disorders (such as psychosis); and visual, auditory or serious language disturbances that can affect the ability to properly answer the questionnaire. Following these criteria, 70 patients were enrolled in the study. Data concerning the age; the educational level; the marital status; the psychiatric and organic personal history; the tumor characteristics and the therapeutic data were collected through interviewing the patients and from their medical records. Then, the patients filled two auto-questionnaires: -The SF-36, in its validated Arabic version, for the assessment of the quality of life. This questionnaire includes 36 items divided into 8 dimensions (physical functioning, physical role functioning, body pain, general health perceptions, vitality [energy/fatigue], social role functioning, emotional role functioning, mental health). Each item is weighted to obtain a score between 0 (worst quality) and 100 (best quality) for each of the 8 dimensions. The scores of the questions that deal with each specific area of the functional health status are calculated on the average to get a final score in each of the 8 dimensions measured. We have used the threshold value of Lean in considering that an overall mean score lower than 66.7 indicated an impaired quality of life (Nicholson and Bigal, 2008). - The Hospital Anxiety and Depression Scale (HAD-S), in its validated Arabic version, for the evaluation of anxiety and depression. This scale was developed by Zigmond and Snaith in 1983 (Zigmond and Snaith, 1983) and is composed of 14 items assessing the anxiety symptoms (7 items) and depression symptoms (7 items). Each item is rated on a four point scale ranging from 0 to 3. In addition to the two scores of anxiety (HADS-A) and depression (HADS-D), the HAD-S allows a categorical distribution in 3 levels: normal level (absence of depression or anxiety) for scores between 0 and 7; limit level (suspicion of depression or anxiety) for scores between 8 and 10; and pathological level (presence of depression or anxiety) for scores between 11 and 21. We have used a version translated in the Tunisian dialect, according to the recommendations of the European Institute of validation of the instruments of measurement. Data management and analysis were performed using SPSS 24.0. The statistical tests used were: the bivariate correlation to determine the relationship between the quantitative variables, T-tests to compare between two means and one-way Anova to compare between more than two means (Level of education, marital status, cancer stage nausea and vomiting during last 4 weeks). Significance levels were set at the 0.05 level. For multivariate analysis, the variables that are statistically associated with the level of 0.2 (Diabetes, chemotherapy, nausea and vomiting post chemotherapy, depression and anxiety symptoms), were introduced in the multiple linear regression model.

Results

The main characteristics of the study population are illustrated in Table 1. The mean age of these patients at the time of diagnosis was 41.13 ± 13.6 years. Ninety per cent of patients were married and 48.6% had a primary educational level. Twenty percent of patients had a personal history of hypertension, 17.1% had a personal history of hypercholesterolemia and 15.7% had a personal history of diabetes. Twenty-seven percent of the patients were classified Stage II and 24.3% were classified stage IV. Fifty-three percent of our patients had a curative treatment, 88.6% had a surgery of the primary tumor, 75.7% had radiotherapy, 94.3% had chemotherapy, 70% had a hormone therapy, and 15.7% had a targeted therapy.
Table 1

Characteristics of the Study Population (n=70)

Characteristics of the study populationNumberPercentage (%)
Marital Status
 Single57
 Married6390
 Divorced22.9
Level of Education
 Illiterate811.4
 Primary school3448.6
 Secondary school2231.4
 Universitary68.6
Stage
 Stage I1724.3
 Stage II1927.1
 Stage III1724.3
 Stage IV1724.3
Surgery of the primary tumor
 Yes6288.6
 No811.4
Radiotherapy
 Yes5375.7
 No1724.3
Chemotherapy
 Yes6694.3
 No45.7
Hormone Therapy
 Yes4970
 No2130
Characteristics of the Study Population (n=70) The mean scores of anxiety and depression in patients were 6.91 ± 4.72 and 6.24 ± 3.88, respectively. Depression and anxiety symptoms were certain among respectively 12.9% and 21.4% of patients. Data from Table 2 shows that the quality of life of patients was altered with an SF-36 mean total score of 53.95 ± 22.66, and the alteration affects the different aspects.
Table 2

Assessments of the Quality of Life According to SF36

Average score of SF36Mean ± standard deviation
Physical functioning61.83 ± 26.57
Physical role functioning25.71 ± 41,91
Emotional role functioning51.42 ± 50,34
Vitality: Energy / fatigue48,14 ± 27,21
Social role functioning59.3 ± 23.98
Mental health67,64 ± 34,96
Bodily pain57,53 ± 26.03
General health perceptions54,29 ± 25.8
Total Score53.95 ± 22.66
Assessments of the Quality of Life According to SF36 There was no correlation between the age of the patients and the SF-36 total score (p = 0.568). The results as shown in Table 3, indicate that there was, on the other hand, a significant correlation between the score of SF36 and the treatment by chemotherapy (p= 0.014) as well as the side effects of chemotherapy such as nausea and vomiting (p=0.01). The socio-demographic factors, the stage of the cancer, the treatment by surgery, radiotherapy or hormone therapy did not affect significantly the quality of life. There was a significant negative correlation between the SF-36 score and the HADS-D score (p= 0.0001) on one hand, and between the SF-36 score and the HADS-A score (p= 0.0001) on the other hand (Table 4).
Table 3

Evaluation of the Quality of Life According to the Various Parameters Studied

VariablesMean of the SF-36 score ± standard deviationP value
Level of Education
 Illiterate40.15 ± 7.5
 Primary school56.32 ± 3.80.328
 Secondaryschool55.64 ± 4.8
 Universitary52.73 ± 9.5
Marital Status
 Single63.69 ± 14.2
 Married53.79 ± 2.70.19
 Divorced34.79 ± 8.8
Diabetes
 Yes60.85 ± 7.20.2
 No52.37 ± 2.9
HTA:
 Yes54.16 ± 6.60.936
 No53.61 ± 3
High cholesterol
 Yes52.57 ± 7.70.849
 No53.96 ± 2.9
Cancer Stage
 I50.62 ± 5
 II58.16 ± 5.40.713
 III50.96 ± 5.3
 IV55.58 ± 6.2
Treatment
 Curative53.43 ± 30.737
 Palliative55.58 ± 6.2
Surgery of the primary tumor
 Yes55.18 ± 2.90.208
 No44.4 ± 6.8
Radiotherapy
 Yes54.06 ± 2.80.953
 No53.61 ± 7
Chemotherapy
 Yes27.25 ± 5.10.014
 No55.57 ± 2.7
Nausea Vomiting during last 4 weeks
 No55.6 ± 3.2
 Slightly63.28 ± 3
 Moderately48.78 ± 9.10.01
 Extremely34.18 ± 6.1
Hormonetherapy
 Yes53.21 ± 3.10.68
 No55.68 ± 5.5
Table 4

Anxiety and Depressive Symptoms and Quality of Life

Correlation between HADS score and Quality of Life (SF36 Total)NumberCorrelation of PearsonP value
HADS-D Score70-0.5680.0001
HADS-A Score70-0.5870.0001
Evaluation of the Quality of Life According to the Various Parameters Studied Anxiety and Depressive Symptoms and Quality of Life The factors significantly associated with the quality of life in multi regression analysis were the marital status (p=0.034) and anxiety symptoms (p=0.032) (Table 5).
Table 5

Factors Correlated to the Quality of Life in the Multi Regression Analysis

VariablesMagnitude of association (ß)Degree of significance (p value)
Marital Status-15.140.034
Diabetes-9.070.094
Chemotherapy-14.350.152
Nausea and vomiting post chemotherapy-2.650.242
Depression symptoms-1.190.214
Anxiety symptoms-1.660.032
Factors Correlated to the Quality of Life in the Multi Regression Analysis

Discussion

Due to the progress of medical care, the number of survivors from cancer has increased significantly during recent years and this increase in survival rates has raised the question of the quality of life of women who had been treated for a breast cancer. This was a cross-sectional study evaluating the quality of life in a sample of 70 women with breast cancer. Taken together, the results of this study suggest that there is an association between the quality of life and chemotherapy and its adverse effects on the one hand, and the anxiety and depressive symptoms on the other hand. There was no significant correlation between the age of patients and the quality of life in this survey. However, a review of the literature had shown that the early age (< 50 years) was considered in most of studies as a predictive factor of a worse quality of life (Jemal et al., 2010; Zainal et al., 2013). There was a significant association between marital status and quality of life in the multi regression analysis in this study and the divorced status was associated with a worse quality of life. This view is supported by Kim et al., (2008) who advocated that marital difficulties are predictive of poor quality of life of patients with breast cancer. No significant association was found between the surgery of the primary tumor and the quality of life in this survey. Weitzner et al., (1997) and Sprangers et al., (1996) noted that, in the short and in the medium term, the mastectomy is associated with a less good body image and so, with a less good quality of life. However, in the long term, much of the current literature (Ganz et al., 2002) found that the type of surgery has no impact on the quality of life. The radiotherapy is often associated with asthenia and with skin disorders, mainly in the acute phase of radiotherapy, which may affect physical and psychological functioning (So et al., 2010). This could explain the statistically significant association identified between the radiation and the decrease in quality of life in several studies (Broeckel et al., 1998; Yen et al., 2006). In this study, no significant association was found, and it can be due to the fact that the patients of the study were not in the acute phase of radiotherapy. In this study, the treatment by chemotherapy and the fact of having nausea and vomiting after chemotherapy were significantly associated with a worse quality of life. It may be due to the short term side effects and cardio-respiratory disorders such as congestive heart failure and pulmonary insufficiency which can occur many years after and which can seriously alter the quality of life in the long term. A number of authors Broeckel et al., (1998); Jacobsen et al., (1995) and Weitzner et al., (1997) have reported that treatment by chemotherapy had been identified as a predictive factor of worse quality of life. It affects mainly the body image and the sexual functioning, and this can impair the quality of life in the short, medium and long term. Chemotherapy is also an important risk factor for neuro-psychic dysfunctions, grouped under the term “chemo brain”. This is considered as an impairment in the memory, the concentration, the attention and the speed of the verbal expression that we can find several years after the end of the treatment (Ganz et al., 2002). In this study, there was no significant association between hormone therapy and the quality of life. Similarly, Hopwood et al., (2007) and Dupont et al., (2007) pointed out the absence of impact of hormone therapy on the quality of life. This view is also supported by Couzi et al., (1995) who concluded that there was significantly more vaginal irritation and side effects in patients under hormone therapy than in those without hormone therapy, but the overall quality of life was not impaired at 6 months post-diagnosis. In this study, there was a significant negative correlation between the scores of HADS-A and the SF36 on the one the hand, and HADS-D and the SF36, on the other hand. This means, that women with depressive or anxious symptoms have a more impaired quality of life. Similarly, Lueboonthavatchai (2007) had established a linear correlation between the depression score and worse quality of life in the patients with cancer. This point of view is supported by the study of Massie (2004), which identified the depression as a strong determinant of the quality of life. Furthermore, the systematic review of Mols et al., (2005) based on ten studies of patients in remission of their breast cancer, asserted that these women have a higher incidence of moderate symptoms of depression compared to healthy women. In addition, these scores of depression are predictive factors of a worse quality of life in all its dimensions, except the dimension of family functioning. In view of all that has been mentioned so far, one may suppose that the treatment of patients with breast cancer should encompass the physical, psychological and social aspects. So, the medical team should take into account the quality of life of the patient with cancer throughout the different stages of treatment. Finally, a number of limitations need to be taken into consideration. First, these findings are limited by the cross sectional design of the study. Secondly, despite the fact that the HADS score has a specificity of 83% and is known as a good tool of screening and following the depression, the opinion of a specialist is always important to diagnose a depression or anxiety disease. In fact, the patients with high HAD-S scores have been referred to psychiatry. Finally, the interpretation of our results still faces a limitation which is the absence of a control group that would allow a better analysis of the found data. In conclusion, the aim of this study was to assess the quality of life of women with breast cancer and to establish its correlation with anxiety and depression on the one hand, and with socio demographic, anatomo clinic and therapeutic parameters, on the other hand. One of the most significant findings emerging from this study is that symptoms of anxiety and depression were significantly associated to an impaired quality of life. The second major finding was that chemotherapy and its side effects such as nausea and vomiting have been significantly associated with alteration of the quality of life. From those results we can emphasize that the whole caregivers’ team must get involved in the management of psychological and psychiatric issues in breast cancer patients.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.
  17 in total

Review 1.  Global patterns of cancer incidence and mortality rates and trends.

Authors:  Ahmedin Jemal; Melissa M Center; Carol DeSantis; Elizabeth M Ward
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.

Authors:  J A Broeckel; P B Jacobsen; J Horton; L Balducci; G H Lyman
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

Authors:  M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

4.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study.

Authors:  Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

5.  Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life.

Authors:  Soo Hyun Kim; Byung Ho Son; Sook Yeon Hwang; Wonshik Han; Jung-Hyun Yang; Seeyoun Lee; Young Ho Yun
Journal:  J Pain Symptom Manage       Date:  2008-03-20       Impact factor: 3.612

6.  Conditioned emotional distress in women receiving chemotherapy for breast cancer.

Authors:  P B Jacobsen; D H Bovbjerg; M D Schwartz; C A Hudis; T A Gilewski; L Norton
Journal:  J Consult Clin Psychol       Date:  1995-02

Review 7.  Prevalence of depression in patients with cancer.

Authors:  Mary Jane Massie
Journal:  J Natl Cancer Inst Monogr       Date:  2004

8.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

Review 9.  Screening and behavioral management: obesity and weight management.

Authors:  Robert Nicholson; Marcelo Bigal
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

10.  The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).

Authors:  Penelope Hopwood; Joanne Haviland; Judith Mills; Georges Sumo; Judith M Bliss
Journal:  Breast       Date:  2007-01-19       Impact factor: 4.380

View more
  6 in total

1.  Biopsychosocial Correlates of Adjustment to Cancer during Chemotherapy: The Key Role of Health-Related Quality of Life.

Authors:  Marco Lauriola; Manuela Tomai
Journal:  ScientificWorldJournal       Date:  2019-03-10

2.  Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer.

Authors:  Benoît Bataille; Bennadji Raoudha; Florence Le Tinier; Laurent Basson; Alexandre Escande; Hélène Langin; Emmanuelle Tresch; Frederik Crop; Franck Darloy; Damien Carlier; Eric Lartigau; David Pasquier
Journal:  Cancers (Basel)       Date:  2020-12-20       Impact factor: 6.639

3.  The Effects of Depression and Anti-Depressants on Quality of Life After Breast Reconstruction: A Post-Hoc Analysis.

Authors:  Kevin M Klifto; Faraah N Bekheet; Michele A Manahan; Kristen P Broderick; Damon S Cooney; Gedge D Rosson; Carisa M Cooney
Journal:  Cureus       Date:  2021-10-11

4.  Gender Differences in Psychosocial, Religious, and Spiritual Aspects in Coping: A Cross-Sectional Study with Cancer Patients.

Authors:  Anahita Rassoulian; Alexander Gaiger; Henriette Loeffler-Stastka
Journal:  Womens Health Rep (New Rochelle)       Date:  2021-10-04

5.  Are Health Literacy and Patient Activation Related to Health Outcomes in Breast Cancer Patients?

Authors:  Chisom Kanu; Carolyn M Brown; Karen Rascati; Leticia R Moczygemba; Michael Mackert; Lalan Wilfong
Journal:  Health Lit Res Pract       Date:  2021-07-15

6.  Psychological distress and health-related quality of life among women with breast cancer: a descriptive cross-sectional study.

Authors:  Nitikorn Phoosuwan; Pranee C Lundberg
Journal:  Support Care Cancer       Date:  2021-12-23       Impact factor: 3.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.